文献速递精神分裂症与精神病性障碍心境障碍物质与行为成瘾

精神分裂症 Medicare 患者一生中的自杀风险

Suicide Risk in Medicare Patients With Schizophrenia Across the Life Span.
PubMed 文献 · JAMA Psychiatry · 2021-01-01

该研究基于 2007–2016 年 5 个全国性回顾性纵向队列,纳入 668 836 例 Medicare 精神分裂症成人患者,随访 2 997 308 人年,记录 2 218 例自杀死亡。总自杀率为每 10 万人年 74.00,标准化死亡比(SMR)为 4.54(95%CI 4.35-4.73);年轻成人绝对与相对风险最高,自杀未遂/自伤及物质使用障碍为重要相关因素。

要点

  • 精神分裂症成人自杀率约为美国一般人群的4.5倍。
  • 18–34岁组自杀率最高(141.95/10万人年,SMR 10.19)。
  • 自杀未遂/自伤和药物使用障碍与自杀风险升高相关。

核心结论

  • 精神分裂症成人自杀风险显著升高,年轻成人绝对与相对风险最高,应重点针对有自杀症状和物质使用的年轻患者开展预防。

研究设计与样本

  • 总队列包括668 836例患者、2 997 308人年随访和2 218例自杀死亡,数据分析时间为2020年9月30日至2021年3月10日。

主要发现

  • 总自杀率为每10万人年74.00,SMR为4.54(95%CI 4.35-4.73);男性自杀率88.96(SMR 3.39;95%CI 3.22-3.57),女性56.33(SMR 8.16;95%CI 7.60-8.75)。
  • 自杀风险随年龄下降,18–34岁组自杀率141.95(SMR 10.19;95%CI 9.29-11.18),65岁及以上组24.01(SMR 1.53;95%CI 1.32-1.77)。
  • 男性(aHR 1.44;95%CI 1.29-1.61)、抑郁(aHR 1.32;95%CI 1.17-1.50)、焦虑(aHR 1.15;95%CI 1.02-1.30)、药物使用(aHR 1.55;95%CI 1.36-1.76)、睡眠障碍(aHR 1.22;95%CI 1.07-1.39)、自杀意念(aHR 1.41;95%CI 1.22-1.63)、自杀未遂或自伤(aHR 2.48;95%CI 2.06-2.98)与自杀风险升高相关。
  • 西班牙裔(aHR 0.66;95%CI 0.54-0.80)和黑人(aHR 0.29;95%CI 0.24-0.35)患者自杀风险低于白人患者。
  • 18–34岁组中,自杀未遂或自伤(aHR 2.57;95%CI 18.20-2.04)和共病药物使用障碍(aHR 1.48;95%CI 1.17-1.88)与自杀风险升高相关,共病抑郁障碍(aHR 0.99;95%CI 0.38-1.26)无显著相关。

临床怎么用

  • 临床应重点关注年轻精神分裂症患者的自杀风险,尤其是有自杀症状和物质使用障碍者。
  • 评估自杀风险时需综合考量性别、抑郁、焦虑、睡眠障碍、自杀意念及自杀未遂/自伤史。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although adults with schizophrenia have an increased risk of suicide, sample size limitations of previous research have hindered characterizations of suicide risk across the life span. OBJECTIVE: To describe suicide mortality rates and correlates among adults with schizophrenia across the life span and standardized mortality ratios (SMRs) for suicide compared with the general US population. DESIGN, SETTING, AND PARTICIPANTS: Five national retrospective longitudinal cohorts of patients with schizophrenia in the Medicare program from January 1, 2007, to December 31, 2016, were identified by age: 18 to 34, 35 to 44, 45 to 54, 55 to 64, and 65 years or older. Death record information was obtained from the National Death Index. The total cohort included 668 836 Medicare patients with schizophrenia, 2 997 308 years of follow-up, and 2218 suicide deaths. Data were analyzed from September 30, 2020, to March 10, 2021. MAIN OUTCOMES AND MEASURES: For each age group, suicide mortality rates per 100 000 person-years and adjusted hazard ratios (aHRs) with 95% CIs of suicide were determined. Suicide SMRs were estimated for the total cohort and by sex and age cohorts standardized to the general US population by age, sex, and race/ethnicity. RESULTS: The study population of adults 18 years and older included 668 836 Medicare recipients with schizophrenia (52.5% men, 47.5% women). The total suicide rate per 100 000 person-years was 74.00, which is 4.5 times higher than that for the general US population (SMR, 4.54; 95% CI, 4.35-4.73) and included a rate of 88.96 for men and 56.33 for women, which are 3.4 (SMR, 3.39; 95% CI, 3.22-3.57) and 8.2 (SMR, 8.16; 95% CI, 7.60-8.75) times higher, respectively, than the rates for the general US population. Suicide rates were significantly higher for men (aHR, 1.44; 95% CI, 1.29-1.61) and those with depressive (aHR, 1.32; 95% CI, 1.17-1.50), anxiety (aHR, 1.15; 95% CI, 1.02-1.30), drug use (aHR, 1.55; 95% CI, 1.36-1.76), and sleep disorders (aHR, 1.22; 95% CI, 1.07-1.39), suicidal ideation (aHR, 1.41; 95% CI, 1.22-1.63), and suicide attempts or self-injury (aHR, 2.48; 95% CI, 2.06-2.98). The adjusted hazards of suicide were lower for Hispanic patients (aHR, 0.66; 95% CI, 0.54-0.80) or Black patients (aHR, 0.29; 95% CI, 0.24-0.35) than White patients. The suicide rate declined with age, from 141.95 (SMR, 10.19; 95% CI, 9.29-11.18) for patients aged 18 to 34 years to 24.01 (SMR, 1.53; 95% CI, 1.32-1.77) for patients 65 years or older. The corresponding declines per 100 000 person-years were from 153.80 (18-34 years of age) to 34.17 (65 years or older) for men and from 115.70 (18-34 years of age) to 18.66 (65 years or older) for women. In the group aged 18 to 34 years, the adjusted hazards of suicide risk were significantly increased for patients with suicide attempt or self-injury (aHR, 2.57; 95% CI, 18.20-2.04) and with comorbid drug use disorders (aHR, 1.48; 95% CI, 1.17-1.88), but not with comorbid depressive disorders (aHR, 0.99; 95% CI, 0.38-1.26) during the year before the start of follow-up. CONCLUSIONS AND RELEVANCE: In this cohort study of adult Medicare patients with schizophrenia, suicide risk was elevated, with the highest absolute and relative risk among young adults. These patterns support suicide prevention efforts with a focus on young adults with schizophrenia, especially those with suicidal symptoms and substance use.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Olfson M, Stroup TS, Huang C, et al. Suicide Risk in Medicare Patients With Schizophrenia Across the Life Span. JAMA Psychiatry. 2021. PMID: 34037667. doi:10.1001/jamapsychiatry.2021.0841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。